CD38 and plasma cell myeloma: ,207,214 In some situations, compromised antigen recognition may actually be beneficial: in a BCMA/CD38 tandem-CAR trial for myeloma, the low-affinity anti-CD38 scFv was placed in a sub-optimal orientation to minimize on-target/off-tumor toxicities (ChiCTR1900026286).212